Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176485 · ClinicalTrials.gov registry record · NA
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
A NA study, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT03176485 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 45 participants.
The verdict
NCT03176485, a NA study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure. A maximum of 45 subjects will be accrued into the overall study we anticipate approximately 25 patients in the Raf inhibitor group and 10 patients each into the Tyrosine Kinase and MEK inhibitor arms of the study.
Interventions
- OTHER Solar Simulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10-17 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03176485
The ClinicalTrials.gov registry entry for NCT03176485 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solar Simulator is the first listed.
NCT03176485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03176485 about?
NCT03176485 is a clinical study titled "Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors". This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure. A maximum of 45 subjects will be accrued into the overall study we anticipate approximately 25 patients in the Raf inhi...
What is the current status of trial NCT03176485?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2014-10-17. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT03176485?
The interventions under investigation include: Solar Simulator (OTHER).
Who is sponsoring clinical trial NCT03176485?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.